[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240241-260261-280; 281+

NICE TAs 241-260

 

REF

 

TITLE

 

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

TA241 

Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) (TA241)  

 

EMCN algorithm

DHFT protocol

TA242

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) (TA242)  

 

EMCN algorithm

DHFT protocol

TA243

Follicular lymphoma - rituximab (review) (TA243)

8.2 Drugs affecting the immune response: 8.2.3 Rituximab & Alemtuzumab

EMCN algorithm

DHFT protocol 

TA244

Chronic obstructive pulmonary disease - roflumilast (TA244)

No drug implications

 

TA245

Venous thromboembolism - apixaban (hip and knee surgery) (TA245)

2.8 Anticoagulants: 2.8.2 Oral anticoagulants

 

TA246 

Venom anaphylaxis - immunotherapy pharmalgen (TA246)

 

 

TA247

Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout: 10.1.3 Drugs which suppress the rheumatic disease process

 

TA248

Diabetes (type 2) - exenatide (prolonged release) (TA248)

 6.1.2.3 Other anti-diabetics

 

TA249

Atrial fibrillation - dabigatran etexilate (TA249)

2.8 Anticoagulants: 2.8.2 Oral anticoagulants

 

TA250

Breast cancer (advanced) - eribulin (TA250)

 

EMCN algorithm

DHFT protocol 

TA251

Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib (TA251)

 

EMCN algorithm

DHFT protocol 

TA252

Hepatitis C (genotype 1) - telaprevir (TA252)

5.3 Antiviral drugs: 5.3.3 Viral Hepatitis

 

TA253 

Hepatitis C (genotype 1) - boceprevir (TA253)

5.3 Antiviral drugs: 5.3.3 Viral Hepatitis

 

TA254

Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)

8.2 Drugs affecting the immune response: 8.2.4 Other Immunomodulating Drugs

 

TA255

Prostate cancer - cabazitaxel (TA255)

 

EMCN algorithm

DHFT protocol

TA256

Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)

2.8 Anticoagulants: 2.8.2 Oral anticoagulants

 

TA257

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) (TA257)

 

Not supported 

TA258

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) (TA258)  

 

EMCN algorithm

DHFT protocol 

TA259

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy) (TA259)

 

EMCN algorithm

DHFT protocol

TA260

Migraine (chronic) - botulinum toxin type A (TA260)

4.7.3 Trigeminal neuralgia, antimigraine drugs, prophylaxis of migraine